Skip to Content

R/R AML: The benefit of intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation

The ASAP study is the first randomized controlled trial to question the benefits of intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation for patients with relapsed or refractory AML. Hear the results here, presented by Johannes Schetelig directly from ASH22 in New Orleans.

Johannes Schetelig

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top